Cancer Medicine (Jun 2021)

Utility of liquid‐based cytology on residual needle rinses collected from core needle biopsy for lung nodule diagnosis

  • Zhihua Lan,
  • Xiaoli Zhang,
  • Xin Ma,
  • Yiyan Hu,
  • Jing Zhang,
  • Fang Yang

DOI
https://doi.org/10.1002/cam4.3949
Journal volume & issue
Vol. 10, no. 12
pp. 3919 – 3927

Abstract

Read online

Abstract Background Core needle biopsy (CNB) has become the most common tissue sampling modality for pathological diagnosis of peripheral lung nodules. However, approximately 10% of pulmonary CNB specimens cannot be unambiguously diagnosed, even with auxiliary techniques. This retrospective study investigated the diagnostic value of liquid‐based cytology on residual pulmonary CNB material collected from needle rinses. Methods Computed tomography‐guided pulmonary CNB specimens and relevant cytology of CNB needle rinses (CNR) from July 2017 to June 2020 were reviewed. A total of 406 patients, each of whom underwent a CNB procedure, were included in the study. Results Of the 406 cases, a more serious diagnosis was rendered by CNR in 6.4% (n = 26) of cases. Furthermore, among these 26 cases, 13 malignancies were confirmed only from CNR. Of the remaining 13 patients with uncertain lesions identified from CNR, six were diagnosed with definite benign lesions from tissue samples, five were found to harbor malignant neoplasms through repeated CNB or follow‐up examination, and two had tuberculosis. The sensitivity (320/332, 96.4%) of combined CNR/CNB (both CNR and CNB) in distinguishing malignancies from benign lesions was higher than that of CNB alone (307/332, 92.5%). A total of 320 malignant neoplasms included 198 cases of primary lung adenocarcinoma and 71 cases of primary lung squamous cell carcinoma. Conclusions CNR with higher nuclear and cytoplasmic resolution than CNB exhibited a high diagnostic efficacy for differentiating malignant from benign lesions in the lung. Moreover, combined CNR/CNB achieved optimal results in reducing the false‐negative rate and the subtyping of non‐small cell lung cancer.

Keywords